Gary Phillips (Pharmaxis Ltd. (ASX: PXS))

Phillips, Gary (Pharmaxis 201505 CEO)

	Organisation	Pharmaxis Ltd. (ASX: PXS)
	Product	anti-inflammatory drug

Record changed: 2020-09-21

Picture [iito] Plain Stupid Simple 650x80px

More documents for Gary Phillips

[1] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....
[2] Boehringer Ingelheim. (12/18/19). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for NASH". Ingelheim & Sydney....
[3] Arix Bioscience plc. (8/6/18). "Press Release: Arix Bioscience Announces First VIPE Investment". London....
[4] Boehringer Ingelheim. (8/24/17). "Press Release: Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis in Debilitating Liver Disease NASH". Ingelheim & Sydney....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Advertise

Gary Phillips (Pharmaxis Ltd. (ASX: PXS))

More documents for Gary Phillips